SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 12b-25

 

Commission File Number 000-54586

 

NOTIFICATION OF LATE FILING

 

(Check One):	☒  Form 10-K ☐ Form 20-F ☐ Form 11-K ☐  Form 10-Q ☐ Form N-SAR
	☐ Form N-CAR
	For Period Ended: December 31, 2018

 

☐ Transition Report on Form 10-K 

☐ Transition Report on Form 20-F 

☐ Transition Report on Form 11-K 

☐ Transition Report on Form 10-Q 

☐ Transition Report on Form N-SAR

 

For the Transition Period Ended: ________________________________________________________

 

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

 

 

PART I - REGISTRANT INFORMATION

 

Boston Therapeutics, Inc. 

Full name of registrant

 

Former name if applicable

 

354 Merrimack Street, #4 

Address of principal executive office

 

Lawrence, Massachusetts  01843 

City, state and zip code

 

PART II - RULE 12b-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

  

☒	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11- K, Form N-SAR, Form N-CSR, or portion thereof, will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

PART III

NARRATIVE

 

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

 

The Company’s Annual Report on Form 10-K for the period ended December 31, 2018 cannot be filed within the prescribed time period because the Company requires additional time for compilation and review to insure adequate disclosure of certain information required to be included in the Form 10-K. The Company’s Annual Report on Form 10-K will be filed on or before the 15^th calendar day following the prescribed due date.

 

Part IV

Other Information

 

(1) Name and telephone number of person to contact in regard to this notification

 

Carl Rausch, CEO	(603)	935-9799
(Name)	(Area Code)	(Telephone Number)

  

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

 

☒  Yes ☐ No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

☐ Yes ☒  No

 

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

Boston Therapeutics, Inc. 

Name of Registrant as Specified in Charter.

 

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: April 1, 2019	By:/s/ Carl Rausch
	Carl Rausch
	Chief Executive Officer